News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

ANTISENSE PHARMA GmbH Trabedersen Shows Good Safety, Tolerability and Promising Survival in Patients with Pancreatic Carcinoma, Malignant Melanoma and Colorectoral Carcinoma



6/2/2009 10:30:02 AM

ORLANDO, Fla.--(BUSINESS WIRE)--Trabedersen (AP 12009), a first in class investigational therapy for the treatment of aggressive tumors, showed a good safety and tolerability profile and encouraging survival data in patients with pancreatic carcinoma, malignant melanoma and colorectal carcinoma. Data from a Phase I/II study, announced at the American Society of Clinical Oncology (ASCO) 2009, will lead to further clinical studies. Currently an additional 24 patients with pancreatic carcinoma or malignant melanoma are being recruited to confirm the promising efficacy and safety results with trabedersen. (Abstract 4619)

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES